Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.
Jullien M, Trudel S, Tessoulin B, Mahé B, Dubruille V, Blin N, Gastinne T, Bonnet A, Lok A, Lebourgeois A, Peterlin P, Garnier A, Chevalier P, Guillaume T, Thomaré P, Le Gouill S, Moreau P, Touzeau C. Jullien M, et al. Ann Hematol. 2019 Jun;98(6):1435-1440. doi: 10.1007/s00277-019-03655-5. Epub 2019 Mar 14. Ann Hematol. 2019. PMID: 30874850
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study.
Trudel S, Tessoulin B, Jullien M, Blin N, Gastinne T, Mahé B, Dubruille V, Bonnet A, Lok A, Chevallier P, Peterlin P, Garnier A, Guillaume T, Le Bourgeois A, Le Gouill S, Moreau P, Touzeau C. Trudel S, et al. Among authors: jullien m. Ann Hematol. 2019 Jun;98(6):1441-1447. doi: 10.1007/s00277-019-03649-3. Epub 2019 Mar 14. Ann Hematol. 2019. PMID: 30874851
Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft.
Jullien M, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Debord C, Mahe B, Dubruille V, Wuilleme S, Blin N, Touzeau C, Gastinne T, Tessoulin B, Le Bris Y, Eveillard M, Duquesne A, Moreau P, Le Gouill S, Bene MC, Chevallier P. Jullien M, et al. Sci Rep. 2020 Sep 21;10(1):15399. doi: 10.1038/s41598-020-72415-7. Sci Rep. 2020. PMID: 32958816 Free PMC article.
Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response.
Makanga DR, Jullien M, David G, Legrand N, Willem C, Dubreuil L, Walencik A, Touzeau C, Gastinne T, Tessoulin B, Le Gouill S, Mahé B, Gagne K, Chevallier P, Clemenceau B, Retière C. Makanga DR, et al. Among authors: jullien m. Oncoimmunology. 2021 Jun 14;10(1):1936392. doi: 10.1080/2162402X.2021.1936392. Oncoimmunology. 2021. PMID: 34178429 Free PMC article.
Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem-cells recipients.
Chevallier P, Coste-Burel M, Le Bourgeois A, Peterlin P, Garnier A, Béné MC, Imbert BM, Drumel T, Le Gouill S, Moreau P, Mahe B, Dubruille V, Blin N, Lok A, Touzeau C, Gastinne T, Jullien M, Vanthygem S, Guillaume T. Chevallier P, et al. Among authors: jullien m. EJHaem. 2021 Jun 1;2(3):520-524. doi: 10.1002/jha2.242. eCollection 2021 Aug. EJHaem. 2021. PMID: 34226903 Free PMC article.
Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy.
Gastinne T, Le Bourgeois A, Coste-Burel M, Guillaume T, Peterlin P, Garnier A, Imbert BM, Drumel T, Mahe B, Dubruille V, Blin N, Lok A, Touzeau C, Tessoulin B, Jullien M, Vanthygem S, Béné MC, Moreau P, Le Gouill S, Chevallier P. Gastinne T, et al. Among authors: jullien m. Br J Haematol. 2022 Jan;196(2):360-362. doi: 10.1111/bjh.17818. Epub 2021 Sep 2. Br J Haematol. 2022. PMID: 34476803 Free PMC article. No abstract available.
Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant.
Le Bourgeois A, Coste-Burel M, Guillaume T, Peterlin P, Garnier A, Imbert BM, Drumel T, Mahé B, Dubruille V, Blin N, Lok A, Touzeau C, Gastinne T, Tessoulin B, Jullien M, Vantyghem S, Moreau P, Le Gouill S, Béné MC, Chevallier P. Le Bourgeois A, et al. Among authors: jullien m. Br J Haematol. 2022 Mar;196(5):e38-e40. doi: 10.1111/bjh.17911. Epub 2021 Oct 20. Br J Haematol. 2022. PMID: 34671982 Free PMC article. No abstract available.
B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.
Jullien M, Le Bourgeois A, Coste-Burel M, Peterlin P, Garnier A, Rimbert M, Imbert BM, Le Gouill S, Moreau P, Mahe B, Dubruille V, Blin N, Lok A, Touzeau C, Gastinne T, Tessoulin B, Vantyghem S, Béné MC, Guillaume T, Chevallier P. Jullien M, et al. Transplant Cell Ther. 2022 May;28(5):279.e1-279.e4. doi: 10.1016/j.jtct.2022.02.018. Epub 2022 Feb 24. Transplant Cell Ther. 2022. PMID: 35218998 Free PMC article.
140 results